Clinical Trials Logo

PPHN clinical trials

View clinical trials related to PPHN.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT06043635 Withdrawn - Clinical trials for Hypoxic Respiratory Failure

Predictors of Inhaled Nitric Oxide Responsiveness in Patients With PPHN

PINOR
Start date: July 15, 2021
Phase:
Study type: Observational

To identify biochemical, clinical, or genetic biomarkers that may predict responsiveness to iNO in neonates with PPHN/HRF. The primary outcome will be identification of any biomarker(s) associated with response to iNO therapy. We will evaluate related biomarkers at various time-points during disease progression and in response to therapy, including single nucleotide polymorphisms in the cyclic adenosine monophosphate/cyclic guanosine monophosphate-Phosphodiesterase (PDE) pathway, indicators of metabolic dysregulation and inflammation, as well as biochemical markers of heart strain. We will perform targeted neonatal echocardiograms to evaluate severity of PPHN and heart function both as an added clinical biomarker and to follow disease progression.

NCT ID: NCT03499418 Withdrawn - Clinical trials for Transient Tachypnea of the Newborn

Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates

PRE-HIFREQ
Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

Transient Tachypnea of the Newborn (TTN) is one of the common causes of neonatal respiratory distress as a result of delayed clearance of fetal lung fluid. Neonates with TTN usually require noninvasive respiratory support (e.g. nasal cannula, nasal CPAP) and may need supplemental oxygen therapy to maintain normal oxygen saturation levels. There have also been reports of "malignant TTN," in which affected children develop persistent pulmonary hypertension of the newborn (PPHN).